Clinical Utility of Cxbladder Monitor for Patients with a History of Urothelial Carcinoma: A Physician-Patient Real-World Clinical Data Analysis

被引:0
作者
Lough, Tony [1 ]
Luo, Qingyang [1 ]
O'Sullivan, Paul [1 ]
Chemasle, Christophe [2 ]
Stotzer, Michael [3 ]
Suttie, James [1 ]
Darling, David [1 ]
机构
[1] Pacific Edge Ltd, Dunedin, New Zealand
[2] Mid Cent Dist Hlth Board, Palmerston North, New Zealand
[3] Southern Dist Hlth Board, Invercargill, New Zealand
关键词
Biomarker; Clinical parameters; Clinical utility; Cystoscopy; Diagnostic; Molecular diagnostic; Physician-patient interaction; Surveillance for recurrence; Urothelial carcinoma;
D O I
10.1007/s40487-018-0059-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: International guidelines advocate regular surveillance of patients following urothelial carcinoma (UC). A validated molecular diagnostic non-invasive urine test, Cxbladder Monitor, correctly identifies patients with a UC history who have low-probability of recurrence. The present study assesses the clinical utility of Cxbladder Monitor in reducing the number and frequency of urologic procedures ordered without missing detection of recurrent UC. Methods: Data from 828 physician-patient assessments were generated from 18 participant physicians who each evaluated the same realworld clinical case data for 30 patients undergoing surveillance for recurrent UC. Each physician ordered tests and procedures and their timing, following review of the patient's demographic data, pre-existing conditions, risk factors and clinical history before and after disclosure of Cxbladder Monitor results. Changes in the number, type and timing of procedures ordered were assessed. Results: The addition of Cxbladder Monitor significantly reduced the overall number of tests ordered by 38.7%, including flexible cystoscopy by 43%, for patients whose Cxbladder Monitor result was low-probability. When the result was elevated-probability, the number of procedures ordered, including cystoscopy, was increased consistent with the increased risk of recurrent UC. Importantly, based on the tests ordered by each physician for each of the patients, all cases of recurrent UC would have been detected. Conclusion: The increase in clinical utility of Cxbladder Monitor for the management of patients undergoing surveillance for recurrent UC was shown to be driven by the reduction in procedures ordered for low-probability patients and for the more invasive procedures ordered for elevated-probability patients. In this study, the total number of procedures ordered, including the number of cystoscopies, was reduced especially in patients with low-probability of UC. The invasive procedures were ordered in a more targeted fashion for elevated-probability patients, without compromising the detection of recurrent UC.
引用
收藏
页码:73 / 85
页数:13
相关论文
共 22 条
[1]   Ras mutation cooperates with β-catenin activation to drive bladder tumourigenesis [J].
Ahmad, I. ;
Patel, R. ;
Liu, Y. ;
Singh, L. B. ;
Taketo, M. M. ;
Wu, X-R ;
Leung, H. Y. ;
Sansom, O. J. .
CELL DEATH & DISEASE, 2011, 2 :e124-e124
[2]  
American Cancer Society, WHAT AR KEY STAT BLA
[3]   EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016 [J].
Babjuk, Marko ;
Boehle, Andreas ;
Burger, Maximilian ;
Capoun, Otakar ;
Cohen, Daniel ;
Comperat, Eva M. ;
Hernandez, Virginia ;
Kaasinen, Eero ;
Palou, Joan ;
Roupret, Morgan ;
van Rhijn, Bas W. G. ;
Shariat, Shahrokh F. ;
Soukup, Viktor ;
Sylvester, Richard J. ;
Zigeuner, Richard .
EUROPEAN UROLOGY, 2017, 71 (03) :447-461
[4]   Surveillance and Treatment of Non-Muscle-Invasive Bladder Cancer in the USA [J].
Barocas, Daniel A. ;
Globe, Denise R. ;
Colayco, Danielle C. ;
Onyenwenyi, Ahunna ;
Bruno, Amanda S. ;
Bramley, Thomas J. ;
Spear, Rachel J. .
ADVANCES IN UROLOGY, 2012, 2012
[5]   Recurrence of high-risk bladder cancer: A population-based analysis [J].
Chamie, Karim ;
Litwin, Mark S. ;
Bassett, Jeffrey C. ;
Daskivich, Timothy J. ;
Lai, Julie ;
Hanley, Jan M. ;
Konety, Badrinath R. ;
Saigal, Christopher S. .
CANCER, 2013, 119 (17) :3219-3227
[6]   Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline [J].
Chang, Sam S. ;
Boorjian, Stephen A. ;
Chou, Roger ;
Clark, Peter E. ;
Daneshmand, Siamak ;
Konety, Badrinath R. ;
Pruthi, Raj ;
Quale, Diane Z. ;
Ritch, Chad R. ;
Seigne, John D. ;
Skinner, Eila Curlee ;
Smith, Norm D. ;
McKiernan, James M. .
JOURNAL OF UROLOGY, 2016, 196 (04) :1021-1029
[7]   Bladder Cancer [J].
Clark, Peter E. ;
Agarwal, Neeraj ;
Biagio, Matthew C. ;
Eisenberger, Mario A. ;
Greenberg, Richard E. ;
Herr, Harry W. ;
Inman, Brant A. ;
Kuban, Deborah A. ;
Kuzel, Timothy M. ;
Lele, Subodh M. ;
Michalski, Jeff ;
Pagliaro, Lance C. ;
Pal, Sumanta K. ;
Patterson, Anthony ;
Plimack, Elizabeth R. ;
Pohar, Kamal S. ;
Porter, Michael P. ;
Richie, Jerome P. ;
Sexton, Wade J. ;
Shipley, William U. ;
Small, Eric J. ;
Spiess, Philippe E. ;
Trump, Donald L. ;
Wile, Geoffrey ;
Wilson, Timothy G. ;
Dwyer, Mary ;
Ho, Maria .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2013, 11 (04) :446-475
[8]   Clinical Utility of Cxbladder for the Diagnosis of Urothelial Carcinoma [J].
Darling, David ;
Luxmanan, Carthika ;
O'Sullivan, Paul ;
Lough, Tony ;
Suttie, James .
ADVANCES IN THERAPY, 2017, 34 (05) :1087-1096
[9]   Non-muscle-invasive bladder cancer surveillance for which cystoscopy is partly replaced by microsatellite analysis of urine: a cost-effective alternative? [J].
de Bekker-Grob, Esther W. ;
van der Aa, Madelon N. M. ;
Zwarthoff, Ellen C. ;
Eijkemans, Marinus J. C. ;
van Rhijn, Bas W. ;
van der Kwast, Theo H. ;
Steyerberg, Ewout W. .
BJU INTERNATIONAL, 2009, 104 (01) :41-47
[10]   What is the clinical utility of genetic testing? [J].
Grosse, Scott D. ;
Khoury, Muin J. .
GENETICS IN MEDICINE, 2006, 8 (07) :448-450